Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Retatrutide treatment lowered both systolic and diastolic blood pressure and reduced total cholesterol, LDL cholesterol, and triglycerides in pooled randomized controlled trials, with no significant change in HDL cholesterol. These findings come from a systematic review and meta-analysis that aimed to clarify the metabolic effects of this triple receptor agonist. The abstract does not report how many patients were included or the treatment duration.

Narrative review — Systematic review and meta-analysis of randomized controlled trials. Interventions: Retatrutide.

Retatrutide significantly reduced systolic blood pressure (WMD -6.79 mmHg, 95% CI -8.36 to -5.23) and diastolic blood pressure (WMD -2.46 mmHg, 95% CI -3.25 to -1.67). Total cholesterol fell by a weighted mean difference of -21.88 mg/dL (95% CI -27.79 to -15.97), LDL-C by -13.10 mg/dL (95% CI -16.10 to -10.10), and triglycerides by -40.90 mg/dL (95% CI -48.50 to -33.30). HDL-C was not significantly changed (WMD -0.01 mg/dL, 95% CI -1.30 to 1.27). Heterogeneity was high for total cholesterol (I² = 84%) and moderate for triglycerides and LDL-C.

This paper is directly relevant to researchers studying Retatrutide because it pools randomized controlled trial evidence on blood pressure and lipid effects of this triple receptor agonist. It does not establish effects on clinical cardiovascular events, optimal dosing, or long-term safety, and the abstract provides no details on the populations or comparator arms of the included trials.

Key findings

• Retatrutide reduced systolic blood pressure by a weighted mean difference of -6.79 mmHg (95% CI -8.36 to -5.23).
• Retatrutide reduced diastolic blood pressure by a weighted mean difference of -2.46 mmHg (95% CI -3.25 to -1.67).
• Total cholesterol decreased by -21.88 mg/dL (95% CI -27.79 to -15.97), with high heterogeneity (I² = 84%).
• LDL cholesterol decreased by -13.10 mg/dL (95% CI -16.10 to -10.10) and triglycerides by -40.90 mg/dL (95% CI -48.50 to -33.30).
• HDL cholesterol did not change significantly (WMD -0.01 mg/dL, 95% CI -1.30 to 1.27).

Limitations

• The abstract reports no author-stated limitations.
• High statistical heterogeneity for total cholesterol (I² = 84%) suggests variability across the included trials.
• Only aggregate meta-analytic results are given; no participant-level data, doses, or trial durations are reported in the abstract.
• The search was limited to four databases and publication bias was not addressed in the abstract.

The record

• Journal: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
• Published: 2026-06-29
• PMID: 42371360 — DOI: 10.1007/s40292-026-00812-6
• Author countries: Mexico

Peptide profiles: Retatrutide.

All indexed evidence: Retatrutide trials & papers.

Related studies: Effect of incretin-based therapies on blood pressure: a systematic review and…, Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in…, Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With…, Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump….